

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human Thrombopoietin/Tpo in direct ELISA.
Source	Monoclonal Mouse IgG ₁ Clone # 1053909
Purification	Protein A or G purified from ascites
Immunogen	Mouse myeloma cell line, NS0-derived human Thrombopoietin/Tpo protein Ser22-Gly353 Accession # P40225
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.


APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Immunohistochemistry	5-25 µg/mL	Immersion fixed paraffin-embedded sections of breast cancer.

DATA

Immunohistochemistry



Detection of immersion fixed paraffin-embedded sections of breast cancer.

Thrombopoietin/Tpo was detected in immersion fixed paraffin-embedded sections of breast cancer using Mouse Anti-Human Thrombopoietin/Tpo Monoclonal Antibody (Catalog # MAB2882) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm and cell surface of cancer cells. View our protocol for [IHC Staining with VisUCyte HRP Polymer Detection Reagents](#).

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	<p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Thrombopoietin (Tpo), is a key regulator of megakaryocytopoiesis and thrombopoiesis. It is principally produced in the liver and is bound and internalized by the receptor Tpo R/c-mpl. Defects in the Tpo-Tpo R signaling pathway are associated with a variety of platelet disorders (1 - 3). The 353 amino acid (aa) human Tpo precursor is cleaved to yield the 332 aa mature protein. Mature human Tpo shares approximately 70% aa sequence homology with mouse and rat Tpo. It is an 80 - 85 kDa protein that consists of an N-terminal domain with homology to Erythropoietin (Epo) and a C-terminal domain that contains multiple N-linked and O-linked glycosylation sites (4, 5). Tissue specific alternate splicing of human Tpo generates multiple isoforms with internal deletions, insertions, and/or C-terminal substitutions (6). Tpo promotes the differentiation, proliferation, and maturation of megakaryocytes (MK) and their progenitors (4, 5, 7). Several other cytokines can promote these functions as well but only in cooperation with Tpo (8, 9). Notably, IL-3 independently induces MK development, although its effects are restricted to early in the MK lineage (8, 9). Tpo additionally promotes platelet production, aggregation, ECM adhesion, and activation (10 - 13). It is cleaved by platelet-derived thrombin following Arg191 within the C-terminal domain and subsequently at other sites upon extended digestion (14). Full length Tpo and shorter forms circulate in the plasma (4, 5). The C terminal domain is not required for binding to Tpo R or inducing MK growth and differentiation (5). Aside from its hematopoietic effects, Tpo is expressed in the brain where it promotes the apoptosis of hypoxia-sensitized neurons and inhibits neuronal differentiation by blocking NGF induced signaling (15, 16).

References:

1. Deutsch, V.R. and A. Tomer (2006) *Br. J. Haematol.* **134**:453.
2. Kaushansky, K. (2005) *J. Clin. Invest.* **115**:3339.
3. Li, J. *et al.* (1999) *Br. J. Haematol.* **106**:345.
4. Bartley, T.D. *et al.* (1994) *Cell* **77**:1117.
5. de Sauvage, F.J. *et al.* (1994) *Nature* **369**:533.
6. Marcucci, R. and M. Romano (2008) *Biochim. Biophys. Acta* **1782**:427.
7. Kaushansky, K. *et al.* (1994) *Nature* **369**:568.
8. Kaushansky, K. *et al.* (1995) *Proc. Natl. Acad. Sci.* **92**:3234.
9. Broudy, V.C. *et al.* (1995) *Blood* **85**:1719.
10. Lok, S.I. *et al.* (1994) *Nature* **369**:565.
11. Chen, J. *et al.* (1995) *Blood* **86**:4054.
12. Oda, A. *et al.* (1996) *Blood* **87**:4664.
13. Van Os, E. *et al.* (2003) *Br. J. Haematol.* **121**:482.
14. Kato, T. *et al.* (1997) *Proc. Natl. Acad. Sci.* **94**:4669.
15. Ehrenreich, H. *et al.* (2005) *Proc. Natl. Acad. Sci.* **102**:862.
16. Samoylenko, A. *et al.* (2008) *Cell. Signal.* **20**:154.